Genetic therapies for ophthalmic disorders such as inherited retinal dystrophies are moving forward in the field and taking steps toward becoming a clinical reality.
The future of gene therapy in retinal disease is a bright one, with many gene therapy companies offering exciting possibilities, Jay S. Duker, MD, a co-founder of Hemera Biosciences, a privately held biotech company, told Ocular Surgery News.
“Gene therapy is being tested in many organ systems, but the retina is one of the best organs in the body to consider gene therapy for several reasons. First, the eye is relatively
Uncategorized